Page 298 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 5 of 6 Original Research

outcome or of what works to fix the problem. In the context Province of Vojvodina, Republic of Serbia. Project name:
of this study, the greatest limitation was the use of US for ‘Cardiometabolic syndrome and its impact on the cognitive
diagnosis of liver steatosis, because this radiological functions in people living with HIV’. Grant number: 114-451-
technique is not able to reliably distinguish steatosis from 497/2016-01.
steatohepatitis, and cannot reliably grade the degree of
inflammation and fibrosis. However, the gold standard, liver References
biopsy, which remains the only reliable procedure to grade
the degree of steatosis, is an invasive method, and we were 1. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic
steatohepatitis. Clin Liver Dis. 2009;13(4):511–531. https://doi.org/10.1016/j.cld.
not able to perform in the absence of proper clinical indication. 2009.07.005
2. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk
of future cardiovascular events among type 2 diabetic patients. Diabetes.
Conclusion 2005;54(12):3541–3546. https://doi.org/10.2337/diabetes.54.12.3541
3. Rinella ME. Nonalcoholic fatty liver disease: A systematic review. JAMA.
HIV mono-infected patients are at high risk for the 2015;313(22):2263–2273. https://doi.org/10.1001/jama.2015.5370
development of hepatic steatosis because of a variety of 4. Marchesini G, Petta S, Dalle Grave R. Diet, weight loss, and liver health in
nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice.
factors, including untreatable systemic inflammation, Hepatology. 2016;63(6):2032–2043. https://doi.org/10.1002/hep.28392
perturbation of fat and fat cell metabolism and the long-term 5. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver
disease: A spectrum of clinical and pathological severity. Gastroenterology.
effects of multiple drugs, including cART and background 1999;116(6):1413–1419. https://doi.org/10.1016/S0016-5085(99)70506-8
liver insults, for example viruses and toxins. The prompt and 6. Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS
Patient Care ST. 2005;19(6):356–3565. https://doi.org/10.1089/apc.2005.19.356
early identification of those at risk is essential if progression 7. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic
to irreversible hepatic fibrosis, cirrhosis and malignancy is to fatty liver disease. Dig Dis. 2010;28:155–161. https://doi.org/10.1159/000282080
be prevented. This study confirms that simple anthropometric 8. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-
measurements including that of VFT measurement have a infected patients referred to a metabolic clinic: Prevalence, characteristics, and
predictors. Clin Infect Dis. 2008;47(2):250–257. https://doi.org/10.1086/589294
role in this regard. Furthermore, that age ≥ 38.5 years may 9. Lombardi R, Sambatakou H, Mariolis I, et al. Prevalence and predictors of liver
identify an important starting point for clinicians who wish steatosis and fibrosis in unselected patients with HIV mono-infection. Dig Liver
Dis. 2016;48(12):1471–1477. https://doi.org/10.1016/j.dld.2016.08.117
to assist their patients who are at risk of progressive liver 10. Pembroke T, Deschenes M, Lebouché B, et al. Hepatic steatosis progresses faster in
disease. HIV mono-infected than HIV/HCV co-infected patients and is associated with liver
fibrosis. J Hepatol. 2017;67(4):801–808. https://doi.org/10.1016/j.jhep.2017.05.011
11. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among
Acknowledgements HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50(5):464–473. https://
doi.org/10.1097/QAI.0b013e318198a88a
Competing interests 12. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and
mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. https://doi.
org/10.1371/journal.pmed.0050203
The authors have no conflict of interests.
13. Stolk RP, Wink O, Zelissen PM, et al. Validity and reproducibility of ultrasonography
for the measurement of intra-abdominal adipose tissue. Int J Obes Relat Metab
Disord. 2001;25:1346–1351. https://doi.org/10.1038/sj.ijo.0801734
Authors’ contributions 14. Philipsen A, Jørgensen ME, Vistisen D, et al. Associations between ultrasound
measures of abdominal fat distribution and indices of glucose metabolism in a
M.V. was the first (main) author. N.B.-J. was responsible for population at high risk of type 2 diabetes: The ADDITION-PRO study. PLoS One.
statistical analysis and data processing. D.I. performed 2015;10(4):e0123062. https://doi.org/10.1371/journal.pone.0123062.g001
ultrasound techniques. Z.D. was responsible for 15. Vecchi VL, Soresi M, Giannitrapani L, et al. Prospective evaluation of hepatic
steatosis in HIV-infected patients with or without hepatitis C virus co-infection. Int
anthropometric data collection. B.S.-G. was the supervisor J Infect Dis. 2012;16(5):397–402. https://doi.org/10.1016/j.ijid.2012.01.011
and was responsible for anthropometric data collection. V.T. 16. World Health Organization. Obesity: Preventing and managing the global
epidemic: Report on a WHO Consultation [homepage on the Internet]. WHO
was the supervisor and technical support and was responsible Technical report series No. 894. Geneva: World Health Organization; 2000 [cited
2019 Feb 10] Available from: https://www.who.int/nutrition/publications/
for patient recruitment and clinical data collection. S.B. was obesity/WHO_TRS_894/en/
the supervisor and technical support and was responsible for 17. Ashwell M, Gibson S. Waist-to-height ratio as an indicator of ‘early health
risk’: Simpler and more predictive than using a ‘matrix’ based on BMI and
patients recruitment and clinical data collection. D.M. was waist circumference. BMJ Open. 2016;6(3):e010159. https://doi.org/10.1136/
the mentor for the main co-author. bmjopen-2015-010159
18. Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio
as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5
Disclaimer could be a suitable global boundary value. Nutr Res Rev. 2010;23(2):247–269.
https://doi.org/10.1017/S0954422410000144
19. Hruby A, Hu FB. The epidemiology of obesity: A big picture. Pharmacoeconomics.
The views expressed in the article are those of the authors 2015;33(7):673–689. https://doi.org/10.1007/s40273-014-0243-x
and not an official position of the institution or funder. 20. Blüher M. The distinction of metabolically healthy from unhealthy obese individuals.
Curr Opin Lipidol. 2010;21:38–43. https://doi.org/10.1097/MOL.0b013e3283346ccc
21. Ibrahim MM. Subcutaneous and visceral adipose tissue: Structural and
Data availability statement functional differences. Obes Rev. 2010;11(1):11–18. https://doi.org/10.1111/
j.1467-789X.2009.00623.x
The data sets generated during or analysed during the 22. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol
Metab. 2004;89:2548–2556. https://doi.org/10.1210/jc.2004-0395
current study are available from the corresponding author on 23. Leroith D. Pathophysiology of the metabolic syndrome: Implications for
reasonable request. the cardiometabolic risks associated with type 2 diabetes. Am J Med Sci.
2012;343(1):13–16. https://doi.org/10.1097/MAJ.0b013e31823ea214
24. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature.
Funding Information 2006;444(7121):881–887. https://doi.org/10.1038/nature05488
25. Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by
This study received funding from the Provincial Secretariat nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the
pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet HIV.
for Higher Education and Scientific Research, Autonomous 1999;9184(354):1112–1115. https://doi.org/10.1016/S0140-6736(99)06102-4

http://www.sajhivmed.org.za 291 Open Access